WO2007068934A3 - Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit - Google Patents

Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit Download PDF

Info

Publication number
WO2007068934A3
WO2007068934A3 PCT/GB2006/004687 GB2006004687W WO2007068934A3 WO 2007068934 A3 WO2007068934 A3 WO 2007068934A3 GB 2006004687 W GB2006004687 W GB 2006004687W WO 2007068934 A3 WO2007068934 A3 WO 2007068934A3
Authority
WO
WIPO (PCT)
Prior art keywords
reverse transcriptase
nucleotide
tenofovir
lamivudine
nucleoside reverse
Prior art date
Application number
PCT/GB2006/004687
Other languages
French (fr)
Other versions
WO2007068934A2 (en
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Curtis Philip Anthony
Amar Lulla
Geena Malhotra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ569349A priority Critical patent/NZ569349A/en
Priority to CA2633603A priority patent/CA2633603C/en
Priority to BRPI0620705-7A priority patent/BRPI0620705A2/en
Priority to EP06820527A priority patent/EP2051703B1/en
Priority to SI200630809T priority patent/SI2051703T1/en
Priority to DE602006015721T priority patent/DE602006015721D1/en
Priority to AT06820527T priority patent/ATE474560T1/en
Priority to JP2008545090A priority patent/JP5231242B2/en
Application filed by Cipla Ltd, Curtis Philip Anthony, Amar Lulla, Geena Malhotra filed Critical Cipla Ltd
Priority to AP2008004533A priority patent/AP2008004533A0/en
Priority to AU2006325404A priority patent/AU2006325404B2/en
Priority to US12/097,387 priority patent/US20080317852A1/en
Publication of WO2007068934A2 publication Critical patent/WO2007068934A2/en
Publication of WO2007068934A3 publication Critical patent/WO2007068934A3/en
Priority to TNP2008000266A priority patent/TNSN08266A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical formulation for the treatment of HIV is provided. The formulation is a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor in which the combination has an increased stability over prior, art combination therapies. The invention also provides a pharmaceutical product containing the formulation.
PCT/GB2006/004687 2005-12-14 2006-12-14 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit WO2007068934A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AT06820527T ATE474560T1 (en) 2005-12-14 2006-12-14 PHARMACEUTICAL COMBINATION OF NUCLEOTIDE AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (SUCH AS TENOFOVIR AND LAMIVUDINE) IN DIFFERENT PARTS OF THE DOSAGE UNIT
BRPI0620705-7A BRPI0620705A2 (en) 2005-12-14 2006-12-14 pharmaceutical formulation in a single unit dosage form, pharmaceutical product, use of a pharmaceutical formulation and use of a nucleoside reverse transcriptase inhibitor or physiologically functional derivative thereof and a nucleotide reverse transcriptase inhibitor or physiologically functional derivative thereof
EP06820527A EP2051703B1 (en) 2005-12-14 2006-12-14 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
SI200630809T SI2051703T1 (en) 2005-12-14 2006-12-14 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
DE602006015721T DE602006015721D1 (en) 2005-12-14 2006-12-14 PHARMACEUTICAL COMBINATION OF NUCLEOTIDE AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (SUCH AS TENOFOVIR AND LAMIVUDIN) IN DIFFERENT PARTS OF THE DOSING UNIT
NZ569349A NZ569349A (en) 2005-12-14 2006-12-14 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
JP2008545090A JP5231242B2 (en) 2005-12-14 2006-12-14 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (tenofovir and lamivudine) in different parts of the dosage form
CA2633603A CA2633603C (en) 2005-12-14 2006-12-14 Pharmaceutical combination
AP2008004533A AP2008004533A0 (en) 2005-12-14 2006-12-14 Pharmaceutical combination
AU2006325404A AU2006325404B2 (en) 2005-12-14 2006-12-14 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
US12/097,387 US20080317852A1 (en) 2005-12-14 2006-12-14 Pharmaceutical Combination
TNP2008000266A TNSN08266A1 (en) 2005-12-14 2008-06-16 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1566/MUM/2005 2005-12-14
IN1566MU2005 2005-12-14
IN1878MU2006 2006-11-13
IN1878/MUM/2006 2006-11-13

Publications (2)

Publication Number Publication Date
WO2007068934A2 WO2007068934A2 (en) 2007-06-21
WO2007068934A3 true WO2007068934A3 (en) 2008-02-21

Family

ID=38163276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/004687 WO2007068934A2 (en) 2005-12-14 2006-12-14 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit

Country Status (15)

Country Link
US (1) US20080317852A1 (en)
EP (1) EP2051703B1 (en)
JP (1) JP5231242B2 (en)
KR (1) KR20080091767A (en)
AP (1) AP2008004533A0 (en)
AT (1) ATE474560T1 (en)
AU (1) AU2006325404B2 (en)
BR (1) BRPI0620705A2 (en)
CA (1) CA2633603C (en)
DE (1) DE602006015721D1 (en)
MA (1) MA30161B1 (en)
NZ (1) NZ569349A (en)
RU (1) RU2008128424A (en)
SI (1) SI2051703T1 (en)
WO (1) WO2007068934A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822155A (en) * 2016-12-29 2017-06-13 东北制药集团股份有限公司 Efavirenz, Lamivudine and piece and preparation method thereof in the Compound Tablet of tenofovir disoproxil fumarate three

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2009037449A1 (en) * 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
PA8809601A1 (en) * 2007-12-24 2009-07-23 Cipla Ltd ANTI-RETROVIRAL COMBINATION
WO2009106960A2 (en) * 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
WO2009106954A1 (en) * 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable dosage forms of lamivudine and tenofovir
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
KR101645759B1 (en) * 2009-02-06 2016-08-04 길리애드 사이언시즈, 인코포레이티드 Tablets for combination therapy
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
WO2010137027A1 (en) 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine
EP2389929A1 (en) * 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of tenofovir
WO2011156594A2 (en) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
CN106511357A (en) 2010-11-19 2017-03-22 吉利德科学公司 Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
US20140193491A1 (en) * 2011-05-30 2014-07-10 Cipla Limited Pharmaceutical antiretroviral composition
CN103211826A (en) * 2013-05-14 2013-07-24 福建广生堂药业股份有限公司 Antiviral pharmaceutical composition as well as preparation method and application thereof
WO2015014737A1 (en) 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayer tablet formulations comprising tenofovir and entecavir
JP6421873B2 (en) * 2014-07-18 2018-11-14 ジェイダブリュ ファーマセウティカル コーポレーション New salt of tenofovir disoproxil
CN104473896B (en) * 2014-12-01 2017-04-19 东莞市金美济药业有限公司 Rapidly-disintegrating lamivudine tablets and preparation process thereof
HRP20211687T1 (en) * 2015-12-02 2022-03-04 Merck Sharp & Dohme Corp. Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
TR201617448A2 (en) 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TENOFOVIR AND EMTRISITAB
RU2644156C1 (en) 2017-02-28 2018-02-08 Александр Васильевич Иващенко Prodrug of polymerase ns5b hcv inhibitor, method for its preparation and application
RU2662160C9 (en) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Combined drug for viral infection therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016755A2 (en) * 1998-09-18 2000-03-30 Glaxo Group Limited Antiviral combinations of lamivudine and adefovir
ZA200110501B (en) * 2001-05-11 2002-04-03 Cipla Medpro Pty Ltd Pharmaceutical composition.
WO2005021001A1 (en) * 2003-09-03 2005-03-10 Tibotec Pharmaceuticals Ltd. Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2006135933A2 (en) * 2005-06-13 2006-12-21 Bristol-Myers Squibb & Gilead Sciences, Llc Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL108838C (en) * 1956-03-27
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IT1264696B1 (en) * 1993-07-09 1996-10-04 Applied Pharma Res PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5733788A (en) * 1996-07-26 1998-03-31 Gilead Sciences, Inc. PMPA preparation
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
UA72207C2 (en) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Pharmaceutical formulations of efavirenz and disintegrants providing for increasing dissolution rate and process of manufacturing such tablets or capsules
ZA200110499B (en) * 2001-05-11 2002-04-03 Cipla Medpro Pty Ltd Pharmaceutical composition.
DE60219965T2 (en) * 2002-04-23 2008-01-17 Lupin Ltd., Mumbai LONG-LIQUID COMPOSITIONS CONTAINING ZIDOVUDINE AND / OR LAMIVUDINE
AU2003231766A1 (en) * 2002-04-26 2003-11-10 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
DE60313657T2 (en) * 2002-11-08 2008-01-03 Smithkline Beecham Corp. ANTIVIRAL COMPOSITIONS
AU2004206827A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016755A2 (en) * 1998-09-18 2000-03-30 Glaxo Group Limited Antiviral combinations of lamivudine and adefovir
ZA200110501B (en) * 2001-05-11 2002-04-03 Cipla Medpro Pty Ltd Pharmaceutical composition.
WO2005021001A1 (en) * 2003-09-03 2005-03-10 Tibotec Pharmaceuticals Ltd. Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2006135933A2 (en) * 2005-06-13 2006-12-21 Bristol-Myers Squibb & Gilead Sciences, Llc Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200357, Derwent World Patents Index; AN 2003-608501, XP002461780 *
FDA: "Guidance for Industry Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV", INTERNET CITATION, May 2004 (2004-05-01), XP002417855, Retrieved from the Internet <URL:http://www.fda.gov/oc/initiatives/hiv/hivguidance.html> [retrieved on 20070131] *
GILEAD ET AL: "Atripla", INTERNET CITATION, July 2006 (2006-07-01), XP002417853, Retrieved from the Internet <URL:http://www.fda.gov/cder/foi/label/2006/021937lbl.pdf> [retrieved on 20070131] *
GILEAD: "Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Sustiva (efavirenz)", INTERNET CITATION, 26 April 2005 (2005-04-26), XP002417804, Retrieved from the Internet <URL:http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle& t=Regular&id=701414&> [retrieved on 20070131] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822155A (en) * 2016-12-29 2017-06-13 东北制药集团股份有限公司 Efavirenz, Lamivudine and piece and preparation method thereof in the Compound Tablet of tenofovir disoproxil fumarate three
CN106822155B (en) * 2016-12-29 2019-10-11 东北制药集团股份有限公司 Piece and preparation method thereof in three Compound Tablet of efavirenz, Lamivudine and tenofovir disoproxil fumarate

Also Published As

Publication number Publication date
NZ569349A (en) 2012-01-12
AU2006325404A1 (en) 2007-06-21
RU2008128424A (en) 2010-01-20
CA2633603A1 (en) 2007-06-21
SI2051703T1 (en) 2011-01-31
BRPI0620705A2 (en) 2011-11-22
MA30161B1 (en) 2009-01-02
JP2009519311A (en) 2009-05-14
DE602006015721D1 (en) 2010-09-02
CA2633603C (en) 2016-09-13
AU2006325404B2 (en) 2012-03-01
ATE474560T1 (en) 2010-08-15
EP2051703A2 (en) 2009-04-29
US20080317852A1 (en) 2008-12-25
AP2008004533A0 (en) 2008-08-31
EP2051703B1 (en) 2010-07-21
KR20080091767A (en) 2008-10-14
JP5231242B2 (en) 2013-07-10
WO2007068934A2 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
WO2007068934A3 (en) Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
TW200716641A (en) Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
NO20071077L (en) Phosphonate analogues for HIV inhibitor compounds
WO2004074266A8 (en) Hiv inhibiting 1,2,4-triazines
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
NO20081592L (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
EP2526934A3 (en) Inhibitors of bruton&#39;s tyrosine kinase
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
IL181987A0 (en) Diaminotriazole derivatives and pharmaceutical compositions containing the same
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
WO2006041773A3 (en) Lactam compounds useful as protein kinase inhibitors
WO2008033562A3 (en) Kinase inhibitor compounds
MX2009003734A (en) Pyrazolopyrimidiwes as cyclin dependent kinase inhibitor.
WO2004005281A8 (en) Inhibitors of tyrosine kinases
WO2004058769A3 (en) Triazolopyridazines as protein kinases inhibitors
WO2007084424A3 (en) Treatment of substance abuse
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
WO2007070562A3 (en) Non-hygroscopic compositions of enterostatin
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2007113243A3 (en) Use of pde 5 inhibitors for the treatment of overactive bladder
WO2005000192A3 (en) Glycogen synthase kinase-3 inhibitors

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2633603

Country of ref document: CA

Ref document number: CR2008-010070

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2008545090

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008061002

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 12008501461

Country of ref document: PH

Ref document number: 2006325404

Country of ref document: AU

Ref document number: MX/A/2008/007776

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 569349

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1340/MUMNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: DZP2008000423

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2006820527

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087016727

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006325404

Country of ref document: AU

Date of ref document: 20061214

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006325404

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 08071866

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2008128424

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12097387

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06820527

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0620705

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080617